johnson&johnson

Global pharma giants Abbott Laboratories and Johnson & Johnson announced their earnings for Q1 2020 last week. Despite being close peers facing a similar crisis situation they took different approaches in sharing information with investors during their earnings conference calls. COVID mention...

Johnson & Johnson (JNJ) reported that its first-quarter 2020 earnings and revenue came in above the analysts’ expectations citing product sales as well as lower costs and expenses. Region-wise, sales were better in the US than international. The Consumer and Pharmaceutical segments experienced...

Earnings of Johnson & Johnson increased and topped the Street view in Q3 helped by a 2% growth in sales. Encouraged by the positive outcome, the management revised up its full-year earnings and sales outlook. The company’s stock gained following the announcement. Read More

Johnson & Johnson surpassed analysts’ expectations on revenue and earnings for the second quarter of 2019. Net sales: $20.6 billion; -1.3% YoY GAAP earnings per share: $2.08; +43% YoY Worldwide medical devices sales declined 7% Not sure how their product pipeline will taking shape in the...

JNJ kicked off pharma earnings as it posted its first-quarter 2019 earnings on Tuesday, April 16, before the opening bell. Reported revenue for the quarter barely changed — inching just 0.1% higher — at $20 billion, while net earnings slipped 14% to $3.7 billion. On a diluted basis, earnings...

JNJ saw sales inch 1% up to $20.4 billion in the fourth quarter of 2018. Operational sales results rose 3.3%. Domestic sales increased 1.5%, while international sales grew 0.4%. Adjusted earnings grew about 13% to $5.4 billion or $1.97 per diluted share While both Medical and Consumer segments...

Arrowhead Pharmaceuticals reports a loss of $0.12 per share in Q4 2018. Arrowhead doesn't report Q4 numbers in the quarterly press release. They only report Q4 numbers in the SEC filing.

Healthcare giant Johnson & Johnson (JNJ) reported a beat on both the top and bottom line expectations as it posted its Q2 2018 earnings. This was aided by a double-digit growth in Pharmaceutical business and the accelerating sales momentum in the Medical Devices business...

Trump has been speaking and tweeting about the higher drug prices for nearly two years and still he has not taken any steps in reducing the prices of the drugs. Pfizer and other pharma companies are taking advantage and increasing their drug prices often. When will this stop...

JNJ reported a 12.6% increase in sales to $20 billion for the first quarter of 2018 as domestic sales grew 6.1% and those from international markets improved about 20%. Net earnings fell slightly to $4.4 billion or $1.60 per share compared to the prior-year period. After adjusting for certain...

Sale of its blockbuster arthritis drug, Remicade, was particularly impacted by the rising influence of biosimilars, especially in the international markets. It needs to be seen how much the company has resisted this trend in the first quarter...

Pfizer (PFE) has been contemplating on selling its consumer healthcare division for some time, and it had found two bidders - British pharmaceutical giants GlaxoSmithKline and Reckitt Benckiser. However, with Reckitt announcing its decision to back out of the race yesterday to pursue its $16.6...

Johnson & Johnson may not be having a great 2018 so far with the stock ticking down about 8% since the year started. But is it time to get rid of the world’s largest pharma company’s shares? Let’s see.

Xarelto is the worst in class of the new blood thinners,” Michael Weinkowitz, the couple’s lawyer, said in a statement. “The serious health complications suffered by thousands of patients could have been avoided if physicians were properly instructed about the risks.” We’ve known all along the...

Can anyone give any insight on the NeuWave ablation division? Good product? Interviewing for Territory Manager role - comp? How is product receive? Good opportunity? Thanks

Johnson&Johnson is discontinuing clinical trials on two potentially blockbuster drugs. Bad timing I would say. I wonder how the company plans to maintain its growth in Pharma sales without these drugs. Source Article

While I was expecting this fate for sirukumab after Glaxo abandoned its partnership on this drug, talacotuzumab's discontinuation was totally unexpected. Two drugs that were so needed! Article source